9:34 AM
 | 
Sep 21, 2018
 |  BC Week In Review  |  Company News  |  Deals

Celenex takeout first of several expected Amicus gene therapy deals

Just weeks after gaining its first FDA approval, Amicus Therapeutics Inc. (NASDAQ:FOLD) has announced its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital spinout Celenex (Columbus, Ohio) for $100 million in cash up front, plus milestones.

More deals are on the way, Chairman and CEO John Crowley said on a conference call Sept. 20 to discuss the deal, with Amicus planning to in-license additional gene therapies in the coming months.

Via Celenex, Amicus gains exclusive, worldwide rights to develop and...

Read the full 402 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >